TAKEDA-ABBOTT PREVACID FOR SHORT-TERM HEALING OF EROSIVE ESOPHAGITIS, SYMPTOM RELIEF FOR UP TO EIGHT WEEKS RECOMMENDED FOR APPROVAL BY FDA COMMITTEE
Executive Summary
Takeda-Abbott Pharmaceuticals' proton pump inhibitor Prevacid (lansoprazole) for short-term healing and symptomatic relief of up to eight weeks in duration for patients with grade 2 and higher acute erosive reflux esophagitis received a unanimous 9-0 recommendation for approval Dec. 2 from FDA's Gastrointestinal Drugs Advisory Committee.